Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.

被引：3
|
作者：
Vogelzang, Nicholas J.
Encarnacion, Carlos A.
Cohn, Allen Lee
DiSimone, Christopher
Rasco, Drew W.
Richards, Donald A.
Taylor, Matthew H.
Dutcus, Corina E.
Stepan, Daniel E.
Shumaker, Robert Charles
Guo, Matthew
Schmidt, Emmett V.
Mier, James Walter
机构：
[1] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[2] Texas Oncol, Waco, TX USA
[3] US Oncol, Rocky Mt Canc Ctr, Denver, CO USA
[4] Arizona Onc Assoc, Tucson, AZ USA
[5] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[6] US Oncol Res, Tyler, TX USA
[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[8] Eisai Inc, Woodcliff Lake, NJ USA
[9] Merck & Co Inc, Kenilworth, NJ USA
[10] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11
引用
收藏
页数：2
相关论文
共 50 条
  • [21] HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer.
    Brown, Jason
    Kaimakliotis, Hristos Z.
    Kelly, William Kevin
    Ammons, Vikki
    Picus, Joel
    Walling, Radhika
    Hashemi-Sadraei, Neda
    Fu, Pingfu
    Margevicius, Seunghee P.
    Adra, Nabil
    Garcia, Jorge A.
    McKay, Rana R.
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [22] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [23] A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
    Jameson, Gayle S.
    Borazanci, Erkut Hasan
    Babiker, Hani M.
    Poplin, Elizabeth
    Niewiarowska, Anna A.
    Gordon, Michael S.
    Barrett, Michael T.
    Ansaldo, Karen
    Lebron, Leticia
    Stoll, Amy C.
    Rosenthal, Adam
    Shemanski, Lynn R.
    Korn, Ronald Lee
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [24] Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
    Kaufman, D
    Raghavan, D
    Carducci, M
    Levine, EG
    Murphy, B
    Aisner, J
    Kuzel, T
    Nicol, S
    Oh, W
    Stadler, W
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (09) : 1921 - 1927
  • [25] The molecular landscape of pembrolizumab and lenvatinib treatment in endometrial cancer.
    Carballo, Erica V.
    Wu, Sharon
    Penn, Courtney A.
    Angara, Kartik
    Thaker, Premal H.
    Oberley, Matthew James
    Herzog, Thomas J.
    Starbuck, Kristen D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.
    Matei, Daniela
    Pant, Alok
    Moroney, John William
    Fleming, Gini F.
    Tanner, Edward
    Swetzig, Wendy M.
    Xu, Jiahui
    Cardenas, Horacio
    Kandpal, Manoj
    Gavrilescu, Andreea
    Chen, Siqi
    Kocherginsky, Masha
    Davuluri, Ramana, V
    Zhang, Bin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Cohn, Allen L.
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    DiSimone, Christopher
    Messing, Mark
    Stepan, Daniel E.
    Dutcus, Corina E.
    Wu, Jane
    Schmidt, Emmett V.
    Orlowski, Robert
    Sachdev, Pallavi
    Shumaker, Robert
    Casado Herraez, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) : 2981 - 2992
  • [28] Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial
    Pectasides, D
    Visvikis, A
    Aspropotamitis, A
    Halikia, A
    Karvounis, N
    Dimitriadis, M
    Athanassiou, A
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (01) : 74 - 79
  • [29] A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
    Weiss, Glen J.
    Waypa, Jordan
    Blaydorn, Lisa
    Coats, Jessica
    McGahey, Kayla
    Sangal, Ashish
    Niu, Jiaxin
    Lynch, Cynthia A.
    Farley, John H.
    Khemka, Vivek
    BRITISH JOURNAL OF CANCER, 2017, 117 (01) : 33 - 40
  • [30] A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari D.
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kraljevic, Silvija
    Ishikawa, Kohei
    Siegel, Abby B.
    Kumada, Hiromitsu
    Young, Louise
    Okusaka, Takuji
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 105 - 105
12345